At Synarc, we feel a deep responsibility for innovation in clinical trials, and we invest heavily in research aimed at reducing uncertainty, time and cost in drug development. We do this through both research collaborations and educational programs with outside scientists at leading universities, government agencies and research foundations. Our unique position provides an ideal vantage point from which to align university research with the special needs of drug development. In this way, Synarc is a gateway to the best minds and talents in the world, developing the tools of tomorrow for clinical research.

Education

• American Society of Clinical Oncology (ASCO) Foundation Grant
• Synarc Research Fellowship, University of Kiel
• American Society of Bone, Mineral and Research (ASBMR) Young Investigator Award

Research and Collaboration

• Comparison of Measurement Techniques in Quantifying Medial Knee Joint Space Width in Osteoarthritis Clinical Studies. OMERACT, OARSI, Hoffman La-Roche, Proctor & Gamble, and Kings College London. PI: Gary Cline.
• Rasch analysis of Whole-Organ MRI Scoring (WORMS). OMERACT, OARSI, and Hoffmann La-Roche. PIs: Phillip Conaghan and Charles Peterfy.
• Responsiveness, Effect Size, and Smallest Detectable Difference of MRI in Knee Osteoarthritis. OMERACT, OARSI, and Hoffmann La-Roche. PIs: David Hunter and Charles Peterfy.
• Development of a Model for the Diagnosis of Early Knee Osteoarthritis (MoDEKO). Canadian Arthritis Network and University of British Columbia. PIs: Jolanda Cibere and John Esdaile.
• Diffraction-Enhanced Imaging, a Novel X-ray Technology for Degenerative Joint Disease. The National Institutes of Health; Rush-Presbyterian-St. Luke's Medical Center, Chicago, IL. PIs: Carol Muehleman and Klaus Kuettner.
• MRI Quantification of Female Sexual Arousal Dysfunction. University of Washington and Pfizer. PI: Ken Maravilla.
• Multicenter Osteoarthritis Trial (MOST). The National Institute of Health, Boston University and University of California San Francisco. PIs: David Felson and Michael Nevitt.
• The Osteoarthritis Initiative, a Knee Health Study. The National Institutes of Health, Pfizer, Novartis, Merck, GlaxoSmithKlein. PI: Gayle Lester.
• Progression of Knee OA: The Role of Local Factors. The National Institutes of Health and Northwestern University. PIs: Leena Sharma and Charles Peterfy.
• Semi-automated Quantification of X-ray Joint Space. John Sharp and Synarc. PIs: John Sharp and Gabriele von Ingersleben.
• Study of Osteoporotic Fractures in Men (MrOS). University of California San Francisco and Oregon Health Sciences University. Synarc is contracted to do the vertebral fracture assessment in this NIH funded study of osteoporosis in men. PIs: Michael Nevitt and Eric Orwoll.
• Survey of Women's Health Across the Nation (SWAN) study. The National Institutes of Health and University of Pittsburgh. PIs: Joel Finkelstein, Fellen B. Gold, Gail A. Greendale, Martica Hall, Karen A. Matthews, Daniel S. McConnell, Lynda H. Powell, Mary Fran Sowers, Barbara Sternfeld, Kim Sutton-Tyrrell, and Gerson Weiss.
• Markers of bone and cartilage turnover in spine and knee OA. Synarc, Inc. PIs: Pr. P. Delmas and P. Garnero.
• Monitoring efficacy of PTH and Alendronate by new biochemical markers of bone turnover. University of California San Francisco. PIs: Dr. Dennis Black and P Garnero.
• Molecular markers of bone, cartilage and Synovium turnover to assess disease progression in patients with hip OA. Negma Pharmaceuticals. PIs: Pr. Maxime Dougados, P. Garnero, and F Juillet.
• Molecular markers of bone and cartilage degradation to assess disease progression in patients with RA (The Cobra Study). Nordic Biosciences. PIs: Pr. Piet Geusens- Fundings, P. Garnero and F Juillet.
• Molecular markers of bone and cartilage degradation to treatment efficacy in patients with RA (The Cobra Study). Nordic Biosciences. PIs: Pr. Piet Geusens, P. Garnero, and F Juillet.
• Molecular markers of cartilage degradation and disease progression in patients with RA on disease remission. Department of clinical epidemiology and biostatistics, VU, University Medical center, Amsterdam, The Netherlands, and Synarc, Inc. PIs: Dr. Alexandre Voskuyl, P. Garnero and F Juillet.
• Influence of collagen crosslinks on bone mechanical properties. Synarc, Inc.. PIs: P. P. Delmas and P. Garnero.
• Markers of bone and cartilage turnover in spondylarthritis. University hospital Maastricht and Synarc, Inc. PIs: Pr. Piet Geusens and P. Garnero
• Molecular markers of bone turnover in Diabetes in the health ABC cohort. University of California San Francisco and Aventis Pharma. PIs: Dr. Ann Schartz and P. Garnero